We found significant correlations between the metagene status and patients’ age (p < 0.001), grade (p < 0.001), ER (p < 0.001), PR (p < 0.001), and HER2 (p = 0.012) statutes and with molecular subtypes of breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.